Zenas Biopharma, Inc.
A clinical-stage biopharmaceutical company developing therapies for autoimmune diseases. Its lead candidate, obexelimab, is a bifunctional antibody that calms overactive B cells without destroying them, and it met its primary goal in a late-stage trial for the rare condition IgG4-related disease. Founded in 2020 by serial entrepreneur Lonnie Moulder, the company takes its name from the ancient Greek "Zenas," meaning "gift of Zeus."
Bought 174.0K
Bought 150.0K
Bought 78.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Moulder Leon O JrChief Executive Officer, Director · 5 transactions | — | 5.84M | — | 174.0K | — |
| Fairmount Funds Management LLC +3 co-filersDirector · 1 transaction | +6.8% | 2.36M | — | 150.0K | — |
| Lu HongboDirector · 2 transactions | — | 849.7K | — | 78.8K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: +402.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.